Craft Technologies Uses Selerity Technologies' Polaratherm
News Aug 09, 2005
Craft Technologies has announced that it has been experimenting with sub-ambient temperature separations, in particular, using the Polaratherm from Selerity Technologies (Salt Lake City, Utah).
The separation of phytochemicals in natural products, including anti-oxidants (carotenoids), has seen renewed interest for their use in nutraceuticals. It is believed that the anti-oxidant capabilities of carotenoids may reduce the risk of developing cancer.
Using Selerity's Polaratherm, Craft Technologies has conducted experiments to separate retinol and retinyl esters, carotenoids, and tocopherols. The results have all demonstrated that sub-ambient and programmable temperature separations using the Polaratherm chromatographic separations.
According to Selerity, its Polaratherm is a HPLC column compartment capable of controlling the temperature from sub zero to 200ºC benefiting from two modes of operation, temperature programming and isothermal.
HPLC column compartment is designed to allow and regulate high, ambient, low or dynamic temperatures for selectivity tuning and improved HPLC separations and the equipment is applicable to most vendor HPLC systems.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE